Drug Trial Radar · NCT02535091
Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures
Last checked: Nov 19, 2026Latest source record: May 14, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,345
Actual
Start
Aug 3, 2016
Primary completion
Mar 31, 2021
Study completion Feb 7, 2022
Sponsor
- Lead sponsor
- SK Life Science, Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 28, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multicenter, open label study to assess the safety and pharmacokinetics of YKP3089 as adjunctive therapy in subjects with partial onset seizures. Initially, subjects taking phenytoin or phenobarbital will be enrolled followed by additional subjects taking anti-epileptic drugs (AED) other than phenytoin and phenobarbital to further investigate long-term safety.
Conditions
- Partial Epilepsy
Interventions
YKP3089Drug
see above
Primary outcomes
What the sponsor says the trial is designed to measure.
- Summary of Treatment-Emergent Adverse Events (TEAEs)Time frame: 1 day to up to 215 weeks after first dose.
Locations
121 sites in 17 countries. Site status is shown where the registry gives one.
Xen Institute
Phoenix, Arizona
Banner-University Medical Center Phoenix
Phoenix, Arizona
Arkansas Epilepsy Program
Little Rock, Arkansas
Kaiser Permanente - Southern California Medical Group
Anaheim, California
Neuro Pain Medical Center
Fresno, California
California Pacific Medical Center
San Francisco, California
Blue Sky Neurology
Englewood, Colorado
Bradenton Research Center Inc
Bradenton, Florida
NW FL Neurology Center
Gulf Breeze, Florida
Emory Brain Health Center
Atlanta, Georgia
Georgia Neurology and Sleep Medicine Associates
Suwanee, Georgia
Hawaii Pacific Neuroscience
Honolulu, Hawaii
Consultants In Epilepsy and Neurology PLLC
Boise, Idaho
MacFarland Clinic
Ames, Iowa
Maine Medical Partners Neurology
Scarborough, Maine
The John Hopkins University School of Medicine
Baltimore, Maryland
Klein, Pavel (Private Practice)
Bethesda, Maryland
Neurology Clinic PC
Waldorf, Maryland
Minneapolis Clinic of Neurology
Minneapolis, Minnesota
Comprehensive Epilepsy Care Center for Children and Adults PC
Chesterfield, Missouri
Northeast Regional Epilepsy Group
Hackensack, New Jersey
NYU Langone Medical Center
New York, New York
University of Rochester Medical Center
Rochester, New York
Montefiore Medical Center
The Bronx, New York
University of Cincinnati, Physicians Company
Cincinnati, Ohio
The Ohio State University Wexner Medical Center
Columbus, Ohio
Riverside Methodist Hospital
Columbus, Ohio
Providence Neurological Specialty Clinic
Portland, Oregon
Penn Epilepsy Center, Department of Neurology
Philadelphia, Pennsylvania
Thomas Jefferson University Comprehensive Epilepsy Center
Philadelphia, Pennsylvania
Medical University of South Carolina
Charleston, South Carolina
Vanderbilt University Medical Center
Nashville, Tennessee
Austin Epilepsy Care Center
Austin, Texas
Hunt Regional Medical Partners
Greenville, Texas
Baylor Scott and White Research Institute
Temple, Texas
University of Virginia, School of Medicine
Charlottesville, Virginia
University of Washington School of Medicine
Seattle, Washington
UW Medicine, Valley Medical Center
Seattle, Washington
Dean and St. Mary's Outpatient Center
Madison, Wisconsin
Hogar de Dia Casa Jesi
Buenos Aires, Argentina
Showing 40 of 121 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.